Board of Directors

Derek DiRocco, PhD
Partner, RA Capital Management

Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for Acrivon, Bambusa Therapeutics, Evommune, Forward Therapeutics, Frontier Medicines, Mineralys, Rivus, Stipple Bio and Syntelios. Previously, Derek covered solid tumor oncology landscapes. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

Derek holds a B.A. in Biology from Holy Cross College and a Ph.D. in Pharmacology from the University of Washington.